World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
30428
World Ranking
11748
National Ranking
6025

Joe Y. Chang publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Joe Y. Chang sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 409 publications — 40th percentile

40% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Joe Y. Chang D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Joe Y. Chang sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Joe Y. Chang is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research mainly falls within the field of Medicine, with a focus on specialized subfields such as Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Radiation, and Surgery.

Their recent scholarly output includes multiple papers published in respected journals, reflecting ongoing contributions to lung cancer research and treatment. Notable papers include:

  • Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology (2022), Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021 (2021), Journal of the National Comprehensive Cancer Network
  • Non-Small Cell Lung Cancer, Version 4.2024 (2024), Journal of the National Comprehensive Cancer Network
  • Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials (2020), The Lancet Respiratory Medicine
  • NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023 (2023), Journal of the National Comprehensive Cancer Network

Their research topics cover a broad range of cancer-related areas, including:

  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Advanced Radiotherapy Techniques
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Radiomics and Machine Learning in Medical Imaging
  • Radiation Therapy and Dosimetry

Joe Y. Chang has published extensively in several prominent journals, particularly:

  • International Journal of Radiation Oncology*Biology*Physics (30 publications)
  • Journal of Thoracic Oncology (13 publications)
  • Journal of the National Comprehensive Cancer Network (11 publications)
  • Radiotherapy and Oncology (10 publications)
  • Journal of Clinical Oncology (5 publications)

Collaboration is a significant aspect of their research activity. Frequent co-authors include Steven H. Lin, Zhongxing Liao, John V. Heymach, James W. Welsh, and Vivek Verma, indicating active engagement in multidisciplinary teams focused on lung cancer and radiation oncology.

Best Publications

  • Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

    Joe Y Chang;Suresh Senan;Marinus A. Paul;Reza John Mehran

  • Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy.

    He Wang;Lei Dong;Jennifer O'Daniel;Radhe Mohan

  • Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines

    David S. Ettinger;Douglas E. Wood;Charu Aggarwal;Dara L. Aisner

  • NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

    David S. Ettinger;David S. Ettinger;Douglas E. Wood;Douglas E. Wood;Dara L. Aisner;Wallace Akerley;Wallace Akerley

  • The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant

    Kobe Reynders;Tim Illidge;Shankar Siva;Shankar Siva;Joe Y. Chang

  • Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer

    James Welsh;Ritsuko Komaki;Arya Amini;Mark F. Munsell

  • NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

    David S. Ettinger;Dara L. Aisner;Douglas E. Wood;Wallace Akerley

  • Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

    Michael B. Bernstein;Sunil Krishnan;James W. Hodge;Joe Y. Chang

  • Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non–small-cell lung cancer

    Joe Y. Chang;Xiaodong Zhang;Xiaochun Wang;Yixiu Kang

  • A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927)

    Gregory M.M. Videtic;Chen Hu;Anurag K. Singh;Joe Y. Chang

  • Assessing Respiration-Induced Tumor Motion and Internal Target Volume Using Four-Dimensional Computed Tomography for Radiotherapy of Lung Cancer

    H. Helen Liu;Peter Balter;Teresa Tutt;Bum Choi

  • Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.

    Willemijn S.M.E. Theelen;Dawei Chen;Vivek Verma;Brian Paul Hobbs

  • Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non–small-cell lung cancer

    Tingyi Xia;Hongqi Li;Qingxuan Sun;Yingjie Wang

  • Intensity-Modulated Proton Therapy Reduces the Dose to Normal Tissue Compared With Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy and Enables Individualized Radical Radiotherapy for Extensive Stage IIIB Non-Small-Cell Lung Cancer: A Virtual Clinical Study

    Xiaodong Zhang;Yupeng Li;Xiaoning Pan;Li Xiaoqiang

  • Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

    Chad Tang;James W. Welsh;Patricia de Groot;Erminia Massarelli

  • Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly.

    Shervin M. Shirvani;Jing Jiang;Joe Y. Chang;James W. Welsh

  • A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.

    Vivek Verma;Tanja Sprave;Waqar M. Haque;Charles B. Simone

  • Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer.

    Joe Y Chang;Peter A Balter;Lei Dong;Qiuan Yang

  • Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly.

    Shervin M. Shirvani;Jing Jiang;Joe Y. Chang;James Welsh

  • Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.

    Gregory M. Videtic;Rebecca Paulus;Anurag K. Singh;Joe Y. Chang

Frequent Co-Authors

Ritsuko Komaki
Ritsuko Komaki The University of Texas MD Anderson Cancer Center
Zhongxing Liao
Zhongxing Liao The University of Texas MD Anderson Cancer Center
James D. Cox
James D. Cox The University of Texas MD Anderson Cancer Center
Radhe Mohan
Radhe Mohan The University of Texas MD Anderson Cancer Center
Pamela K. Allen
Pamela K. Allen The University of Texas MD Anderson Cancer Center
Jack A. Roth
Jack A. Roth The University of Texas MD Anderson Cancer Center
Xiaodong Zhang
Xiaodong Zhang The Ohio State University
John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center
Stephen G. Swisher
Stephen G. Swisher The University of Texas MD Anderson Cancer Center
Charles Lu
Charles Lu The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Preparing for a career in medicine isn’t limited to traditional medical degrees. Many students explore alternative healthcare paths, especially through online study options. If you’re interested in nursing but wish to skip lengthy pre-admission testing, consider enrolling in a nursing school that does not require teas test. These programs offer a streamlined entry into nursing for those eager to begin caring for patients quickly.

For individuals seeking leadership positions in healthcare, accelerated healthcare programs can help you earn a degree in less time and begin advancing your career sooner. Registered Nurses looking to specialize further might be interested in rn to np bridge programs, which enable experienced nurses to transition into advanced practice roles, such as nurse practitioner.

For those with a passion for wellness, nutrition, and preventative care, there are a variety of reputable online nutrition degree programs available. These pathways offer flexibility and the opportunity to build knowledge that supports healthy communities. No matter your interests, online degree options can help you carve out a fulfilling role in the healthcare sector.

Best Scientists Citing Joe Y. Chang

Trending Scientists

Recently Published Articles